Keros Therapeutics, Inc.

Contributing Author

Recent Articles by Keros Therapeutics, Inc.

Sep-29	Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda KROS GlobeNewswire
Sep-28	Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD KROS GlobeNewswire
Sep-08	Keros Therapeutics Announces $5 Million Share Repurchase Authorization KROS GlobeNewswire
Aug-03	Keros Therapeutics Reports Second Quarter 2026 Financial Results KROS GlobeNewswire
Jul-30	Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda KROS GlobeNewswire
Jun-25	Keros Therapeutics Appoints Anne Prener to its Board of Directors KROS KROS +5.57% GlobeNewswire
Jun-01	Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference KROS GlobeNewswire
May-14	Keros Therapeutics Reports Recent First Quarter 2026 Financial Results KROS -8.34% GlobeNewswire
Mar-09	Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference KROS GlobeNewswire
Mar-09	Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS KROS GlobeNewswire
Mar-04	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results KROS KROS -14.96% GlobeNewswire
Feb-26	Keros Therapeutics Appoints Charles Newton to its Board of Directors KROS KROS -5.59% GlobeNewswire
Feb-18	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences KROS GlobeNewswire
Nov-20	Keros Therapeutics Announces Final Results of Tender Offer KROS GlobeNewswire
Nov-19	Keros Therapeutics Announces Preliminary Results of Tender Offer KROS GlobeNewswire
Nov-05	Keros Therapeutics Reports Third Quarter 2025 Financial Results KROS GlobeNewswire
Oct-20	Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares KROS +9.83% GlobeNewswire
Oct-15	Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital KROS GlobeNewswire
Sep-08	Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting KROS GlobeNewswire
Aug-28	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences KROS GlobeNewswire
Aug-20	Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy KROS GlobeNewswire
Aug-06	Keros to Exclusively Prioritize the Clinical Advancement of KER-065 KROS KROS -7.29% GlobeNewswire
Aug-06	Keros Therapeutics Reports Second Quarter 2025 Financial Results KROS KROS -7.29% GlobeNewswire
Jul-17	Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept KROS GlobeNewswire
Jun-09	Keros Announces Return of $375 Million in Excess Capital to Stockholders KROS -6.32% GlobeNewswire
Jun-06	Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference KROS GlobeNewswire
May-29	Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring KROS GlobeNewswire
May-27	Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Keros' Director Nominees KROS GlobeNewswire
May-19	Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value KROS GlobeNewswire
May-12	Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference KROS GlobeNewswire
May-08	Keros Reinforces Commitment to Maximizing Stockholder Value KROS GlobeNewswire
May-06	Keros Therapeutics Reports Recent First Quarter 2025 Financial Results KROS -5.46% GlobeNewswire

Keros Therapeutics, Inc.

Recent Articles by Keros Therapeutics, Inc.

Upgrade your Finviz experience